Celldex Therapeutics, Inc. company, formerly known as AVANT Immunotherapeutics, Inc., was founded in 1983 and is headquartered in Needham, Massachusetts. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of vaccines and targeted immunotherapeutics for the treatment of cancer, infectious, and inflammatory diseases. The company focuses on the use of tumor-specific targets and human monoclonal antibodies to precisely deliver therapeutic agents through targeted immunization approach. It also offers bacterial vector delivery technologies with manufacturing and preservation processes that offer the potential for a new generation of infectious disease vaccines.Celldex Company's products include Rotarix for the prevention of rotavirus infection; and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Its product pipeline also consists of products in various stages of development, including CDX-110, which is undergoing evaluation in a Phase 2/3 clinical trial for the treatment of glioblastoma multiforme, an aggressive form of brain cancer; CDX-1307, a product based on its proprietary APC Targeting Technology, which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast, and colon cancer; a TP10, a complement inhibitor for transplantation and other indications; and three candidates based on its oral, rapidly-protecting, single-dose, and temperature-stable vaccine technology, such as combination vaccines for travelers, the military, and health needs. AVANT Immunotherapeutics has collaborative agreements with GlaxoSmithKline for the development and commercialization of oral rotavirus vaccine; Pfizer, Inc. for discovery and development of vaccines to protect animals, and to develop CDX-110; and Select Vaccines Limited for the development of viral vaccines.

QLT Inc. company was founded in 1981 and is headquartered in Vancouver, Canada. QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, as well as OT-730, a prodrug of a beta adrenergic antagonist (a type of beta blocker) under investigation for the treatment of glaucoma.

Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies. Repligen also licenses its patent covering the use of CTLA4-Ig, a regulator of the activity of the immune system, and receives royalties from Bristol-Myers Squibb based on their U.S. Sales of Orencia. The company's development stage products include RG1068, human secretin for improved MRI of the pancreas; RG2417, uridine for bipolar depression; HDAC inhibitors for Friedreich's ataxia; and RG-SMA for spinal muscular atrophy. The company sells its Protein A products primarily through value-added resellers, as well as through distributors internationally.

Haw Par Corporation Limited is engaged in licensing the Tiger trademarks, and owning investments for long-term holding purposes. It has four segments: manufacturing, marketing and trading of Healthcare products; provision of leisure-related services; property rental, and investments in securities. Its healthcare division principally manufactures and distributes analgesic products under the Tiger Balm and Kwan Loong brand. Leisure division provides family and tourist oriented leisure alternatives mainly in the form of oceanariums. Property division owns and leases out several investment properties in the Asia region. Investment division engages in investing activities, mainly in quoted and unquoted securities in Asia region. In December 2009, the Company announced that it completed the dissolution of the subsidiaries Haw Par Realty Private Limited, HPH Property Sdn Bhd, Kwan Loong Industries Sdn Bhd, Haw Par Tiger Balm (Hong Kong) Limited and Kwan Loong Oils (HK) Limited.

Otsuka America is US headquarters of Japan's Otsuka Pharmaceutical. Otsuka America oversees pharmaceutical research and development, marketing, and distribution of both prescription drugs and over-the-counter (OTC) medicines. The holding company's pharmaceutical subsidiaries include Otsuka America Pharmaceutical (prescription drug marketing), Otsuka Maryland Medicinal Laboratories (research), Cambridge Isotope Laboratories (chemical ingredients), and Pharmavite (nutritionals). To help wash down its pills Otsuka America also holds consumer beverage makers Crystal Geyser (bottled water), Ridge Vineyards (wine), and Soma Beverage Company (specialty bottled water).

Bio-Botanica was founded in 1972 by CEO Frank D'Amelio. Bio-Botanica Inc. company develops and manufactures a variety of botanical extracts used by customers throughout the US and internationally, in the nutraceutical, food and beverage, and cosmetics industries. Bio-Botanica's more than 300 extracts come in solid, semi-solid, powdered, and liquid forms and are used as both active ingredients and preservatives in products ranging from teas to soaps and homeopathic remedies. The company also produces its own line of consumer products, including extracts and blended nutritional supplements, which are sold through retailers under the Nature's Answer brand.

Pfizer decided to put a Cork in it, the pharmaceutical giant made Ireland one of the world's largest manufacturers and exporters of pharmaceuticals. Pfizer Ireland Pharmaceuticals is part of the Pfizer Global Manufacturing division. Parent company Pfizer began operating in Ireland in 1969 with a citric acid manufacturing plant and now operates about a dozen Irish plants. Its manufacturing facilities are involved in the development, formulation, and bulk manufacture of human pharmaceuticals (especially cardiovascular drugs) and animal health care products, as well as sterile pharmaceutical products and active pharmaceutical ingredients.

Cephalon, Inc. was founded in 1987 and is headquartered in Frazer, Pennsylvania. Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The company's pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa.

Since its founding in 2004, Anthera Pharmaceuticals' operations have consisted primarily of research and development activities. A biopharmaceutical company, Anthera Pharmaceuticals develops drug treatments for respiratory, cardiovascular, and immunological diseases. Its current candidates, which are in various phases of clinical development, include therapies for acute coronary syndrome (inflammation of heart muscle), lupus, and sickle cell disease. The company also has treatments for asthma and dermatitis in earlier stages of development. The company filed an initial public offering (IPO) in mid-2009.

Thallion Pharmaceuticals develops products for the treatment of cancer and infections. Thallion has three leading products in various developmental stages. The Shigamabs drug candidate is targeted to treat Shigatoxin producing E. coli infections. The company's TLN-232 is being evaluated as a treatment of a number of cancer conditions. Its TLN-4601 is another oncology focused treatment. Thallion was considering the possible sale of the company until it received a nearly $9 million capital infusion through an arrangement with Premium Brands. Though Thallion's operations didn't change, and it's still owned by the same shareholders, the move did take the company public.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.